SCM
PRVB

Soleus Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Soleus Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-105,941
Closed -$1.79M – 87
2020
Q4 		$1.79M Sell
105,941
-33,477
-24% -$502K 0.24% 40
2020
Q3 		$1.79M Buy
139,418
+79,518
+133% +$1M 0.95% 33
2020
Q2 		$845K Buy
+59,900
New +$756K 0.48% 44

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Soleus Capital Management's PRVB Position: Q1 2021 in Review

Soleus Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2021, closing a stake of 105,941 shares — an estimated $1.79M sold.

Soleus Capital Management first reported a position in PRVB in Q2 2020 and held it in 3 quarters. The position peaked at $1.79M in Q4 2020. 120 funds tracked by Wall St. Rank hold PRVB as of Q1 2021.

  • Soleus Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Soleus Capital Management sold 105,941 Provention Bio, Inc. Common Stock shares in Q1 2021, an estimated $1.79M.
  • Soleus Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Soleus Capital Management's Provention Bio, Inc. Common Stock position peaked at $1.79M in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2021.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.